Therapeutic Variables in Cataract Surgery

This study has been completed.

First Received: November 30, 2006 Last Updated: August 17, 2007 History of Changes

Sponsor:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00407017

Purpose

The purpose of this study is to compare patient outcomes in following cataract surgery in patients randomized to one of two surgical kits.

Condition	Intervention	Phase
Cataract Surgery	Drug: Gatifloxacin Drug: Ketorolac LS Drug: Pred Forte Drug: Moxifloxacin Drug: Nepafenac Drug: EconoPred Plus	Phase IV

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Active Control, Parallel Assignment

Resource links provided by NLM:

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Males or females scheduled to undergo cataract surgery
Patients can be receiving monofocal IOLs only
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion Criteria:

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407017

Locations

United States, Florida
The Center for Excellence in Eye Care
Miami, Florida, United States, 33176

Sponsors and Collaborators

Innovative Medical

Investigators

Principal Investigator:

William Trattler, MD

The Center For Excellence in Eye Care

More Information

No publications provided

Study ID Numbers:	5264-T
Study First Received:	November 30, 2006
Last Updated:	August 17, 2007
ClinicalTrials.gov Identifier:	NCT00407017 History of Changes
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Anti-Infective Agents
Antineoplastic Agents
Methylprednisolone
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Lens Diseases
Neuroprotective Agents
Hormones
Moxifloxacin
Therapeutic Uses
Cataract

Methylprednisolone Hemisuccinate
Antineoplastic Agents, Hormonal
Eye Diseases
Gastrointestinal Agents
Methylprednisolone acetate
Protective Agents
Glucocorticoids
Pharmacologic Actions
Gatifloxacin
Autonomic Agents
Prednisolone
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 08, 2010